CARL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

5 Analyst Rating

Wall Street analysts forecast CARL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CARL is 20.25 USD with a low forecast of 18.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.600

Low

18.00

Averages

20.25

High

24.00

Current: 12.600

Low

18.00

Averages

20.25

High

24.00

UBS

Neutral -> Buy

upgrade

2025-12-03

Reason

UBS

Price Target

2025-12-03

upgrade

Neutral -> Buy

Reason

UBS upgraded Carlsberg to Buy from Neutral with a price target of DKK 1,060, up from DKK 810.

UBS

Neutral -> Buy

upgrade

2025-12-03

Reason

UBS

Price Target

2025-12-03

upgrade

Neutral -> Buy

Reason

UBS upgraded Carlsberg to Buy from Neutral with a price target of DKK 1,060, up from DKK 810. Carlsberg's move into the European soft drinks category comes at a time when the company is seeing some greenshoots for its beer business in Asia following two years of declines, the analyst tells investors in a research note. The firm sees a return to consistent volume growth.

BTIG

Ryan Zimmerman

Buy

maintain

$21 -> $24

2025-11-07

Reason

BTIG

Ryan Zimmerman

Price Target

$21 -> $24

2025-11-07

maintain

Buy

Reason

BTIG analyst Ryan Zimmerman raised the firm's price target on Carlsmed to $24 from $21 and keeps a Buy rating on the shares after its Q3 earnings beat. The company's top-line outperformance came from increased surgeon growth coupled with steady productivity of 1.9 units/surgeon, the analyst tells investors in a research note.

Piper Sandler

Matt O'Brien

Overweight

initiated

$18

2025-08-18

Reason

Piper Sandler

Matt O'Brien

Price Target

$18

2025-08-18

initiated

Overweight

Reason

Piper Sandler analyst Matt O'Brien initiated coverage of Carlsmed with an Overweight rating and $18 price target. The company 3D-printed spinal implants that are custom fit to each patient's anatomy and is currently the only one of its kind on the market, the analyst tells investors in a research note. The firm believes the capital from the initial public offering will Carlsmed with its sales force expansion efforts, driving further surgeon adoption and market penetration.

BTIG

Buy

initiated

$21

2025-08-18

Reason

BTIG

Price Target

$21

2025-08-18

initiated

Buy

Reason

BTIG initiated coverage of Carlsmed with a Buy rating and $21 price target. The firm views the company as "differentiated" in the $13.4B lumbar spinal implant market. Carlsmed is commercializing its FDA approved Aprevo platform, which combines artificial intelligence-driven pre-operative planning software with patient-specific interbody implants, the analyst tells investors in a research note. BTIG believes Carlsmed has solved many of the issues that have prevented the scale of customized musculoskeletal implants in the past.

BofA

Travis Steed

Buy

initiated

$16

2025-08-18

Reason

BofA

Travis Steed

Price Target

$16

2025-08-18

initiated

Buy

Reason

BofA analyst Travis Steed initiated coverage of Carlsmed with a Buy rating and $16 price target. The firm says the company's Aprevo platform is ushering in a new standard of care in spine fusion surgery with custom 3D printed interbody implants. BofA's views its forecast of Carlsmed adding 20-25 new surgeons each quarter through 2027 as conservative.

Valuation Metrics

The current forward P/E ratio for Carlsmed Inc (CARL.O) is -8.13, compared to its 5-year average forward P/E of -8.23. For a more detailed relative valuation and DCF analysis to assess Carlsmed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.23

Current PE

-8.13

Overvalued PE

-6.49

Undervalued PE

-9.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.57

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-7.80

Undervalued EV/EBITDA

-13.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.03

Current PS

0.00

Overvalued PS

7.13

Undervalued PS

4.93

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CARL News & Events

Events Timeline

No data

News

1.0

12-16Globenewswire

Carlsmed CEO Mike Cordonnier to Present at J.P. Morgan 2026 Healthcare Conference

5.0

12-09NASDAQ.COM

CARL Introduces Aprevo Cervical Platform for Customized Spine Surgery

3.5

12-03Globenewswire

Carlsmed Launches aprevo® Technology Platform for Cervical Fusion Surgeries

People Also Watch

Frequently Asked Questions

What is Carlsmed Inc (CARL) stock price today?

The current price of CARL is 12.6 USD — it has decreased -2.4 % in the last trading day.

What is Carlsmed Inc (CARL)'s business?

Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights intended to improve the digital surgical planning process. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.

What is the price predicton of CARL Stock?

What is Carlsmed Inc (CARL)'s revenue for the last quarter?

Carlsmed Inc revenue for the last quarter amounts to 13.07M USD, decreased % YoY.

What is Carlsmed Inc (CARL)'s earnings per share (EPS) for the last quarter?

Carlsmed Inc. EPS for the last quarter amounts to -0.40 USD, decreased % YoY.

What changes have occurred in the market's expectations for Carlsmed Inc (CARL)'s fundamentals?

The market is revising Upward the revenue expectations for Carlsmed, Inc. (CARL) for FY2025, with the revenue forecasts being adjusted by 6.7% over the past three months. During the same period, the stock price has changed by -16.33%.

How many employees does Carlsmed Inc (CARL). have?

Carlsmed Inc (CARL) has 100 emplpoyees as of December 17 2025.

What is Carlsmed Inc (CARL) market cap?

Today CARL has the market capitalization of 335.07M USD.